About 1% of the Indian population suffers from heart failure (HF) with an estimated mortality of 0.1-0.16 million individuals per year. 1 There have been significant advances in early diagnosis, treatment, and prognosis of HF. B‐type natriuretic peptide (BNP) and its N‐ terminal fragment (NT-proBNP) are the initial diagnostic test used in India to diagnose, assess the severity and prognosis of HF. 2,3 NT-proBNP is recognized as a gold standard biomarker in HF 4 Biologically inert NT-proBNP peptide is a more stable biomarker for HF than active BNP hormone which gets degraded in the body much faster.
5-8 NT-proBNP has lower biologically variability compared to BNP and is less likely to be perturbed by acute stimuli. 5-8 NT-proBNP is stable for a longer period of time (half-life of 120 min; 6 times longer than BNP). 5-8 ESC: The European Society of Cardiology; LVEF: Left ventricular…
